HTA ID Drug Brand Indication Assessment status Date
- Bosentan Tracleer® Treatment pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO Functional Class (FC) III and WHO FC II.  It is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease. Rapid Review complete 8th July 2014
- Bosutinib Bosulif® Treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options. Rapid Review complete 25th September 2013
- Brentuximab vedotin Adcetris® Treatment of adult patients with relapsed or refractory CD30 positive Hodgkin lymphoma following autologous stem cell transplant  or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option and is also indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma. NCPE Assessment Process Complete 11th April 2014
- Brentuximab vedotin Adcetris® Treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy (license extension). Rapid Review complete 6th March 2018
19058 Brentuximab vedotin Adcetris® Treatment of adult patients with CD30+ Hodgkin’s lymphoma at increased risk of relapse or progression following autologous stem cell transplant. NCPE Assessment Process Complete 22nd October 2021
21010 Brentuximab vedotin Adcetris® In combination with cyclophosphamide [C], doxorubicin [H] and prednisone [P] (CHP) in combination for use in adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL). Rapid Review complete 23rd April 2021
23045 Brexucabtagene Autoleucel Tecartus® Adults 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia Full HTA submission received from Applicant 18th January 2024
- Brigatinib Alunbrig® As monotherapy for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib. Rapid Review complete 11th December 2018
20031 Brigatinib Alunbrig® As monotherapy for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK-inhibitor. Rapid Review complete 6th August 2020
- Brimonidine Mirvaso® Treatment of facial erythema of rosacea in adult patients. Rapid Review complete 7th May 2014
- Brivaracetam Briviact® As adjunctive therapy in the treatment of partial-onset seizures (POS) with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy. Rapid Review complete 22nd March 2016
- Brodalumab Kyntheum® Treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy. Rapid Review complete 29th August 2017
20009 Brolucizumab Beovu® Treatment of neovascular (wet) age-related macular degeneration. Rapid Review complete 7th April 2020
- Budesonide Jorveza® Treatment of eosinophilic esophagitis (EoE) in adults (older than 18 years of age). Rapid Review complete 26th May 2020
22067 Bulevirtide Hepcludex® Chronic hepatitis delta (CHD) infection in plasma (or serum) HDV RNA-positive adult patients with compensated liver disease. NCPE Assessment Process Complete 22nd February 2024
22037 Buprenorphine/Naloxone Zubsolv® As substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Treatment is intended for use in adults and adolescents over 15 years of age who agreed to be treated for addiction. Rapid Review complete 21st June 2022
22056 Buprenorphine Buvidal® Treatment of opioid dependence within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 years or over. Rapid Review complete 23rd September 2022
- Buprenorphine/Naloxone Suboxone® Management of opiate addiction NCPE Assessment Process Complete 22nd May 2014
- Burosumab Crysvita® Treatment of X-linked hypophosphataemia (XLH) with radiographic evidence of bone disease in children 1 year of age and older and adolescents with growing skeletons. NCPE Assessment Process Complete 12th March 2020
23005 Burosumab Crysvita® Burosumab (Crysvita®) is indicated for X-linked hypophosphataemia in adult patients. Awaiting response from Applicant 6th March 2024
- C1inhibitor (human) Cinryze® Treatment and pre-procedure prevention of angioedema attacks in adults and adolescents with hereditary angioedema (HAE). Routine prevention of angioedema attacks in adults and adolescents with severe and recurrent attacks of hereditary angioedema (HAE), who are intolerant to or insufficiently protected by oral prevention treatments, or patients who are inadequately managed with repeated acute treatment Rapid Review complete 15th November 2012
- Cabazitaxel Jevtana® Treatment of patients with hormone-refractory metastatic prostate cancer previously treated with docetaxel-containing treatment regimen. NCPE Assessment process complete 13th March 2012
21026 Cabotegravir/Rilpivirine Vocabria®/Rekambys® HIV-1 infection in adults who are virologically suppressed on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class. Rapid Review complete 21st July 2021
- Cabozantinib Cabometyx® Treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy. NCPE Assessment process complete 4th July 2018
22018 Cabozantinib/Nivolumab Cabometyx®/Opdivo® First-line treatment of advanced renal cell carcinoma in adults. Rapid Review complete 11th May 2022
- Cabozantinib Cometriq® Treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma. For patients in whom Rearranged during Transfection (RET) mutation status is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision. Rapid Review complete 13th August 2014
22063 Calcifediol monohydrate Dnord® Treatment of vitamin D deficiency (i.e., 25(OH)D levels <25 nmol/L) in adults, for the prevention of vitamin D deficiency in adults with identified risks such as in patients with malabsorption syndrome, chronic kidney disease mineral and bone disorder (CKD-MBD) or other identified risks, and as an adjuvant for the specific treatment of osteoporosis in patients with vitamin D deficiency or at risk of vitamin D deficiency. Rapid Review complete 13th October 2022
- Calcipotriol/Betamethasone dipropionate Enstilar® For the topical treatment of psoriasis vulgaris in adults Rapid review complete 22nd June 2016
- Camellia sinensis, folium (green tea leaf) Catephen® Cutaneous treatment of external genital and perianal warts (condylomataacuminata) in immunocompetent patients from the age of 18 years. Rapid Review complete 10th July 2015
- Canagliflozin Invokana® Treatment of type 2 diabetes as monotherapy or add-on combination therapy to other glucose-lowering medicinal products including insulin NCPE Assessment Process complete 29th August 2014
20004 Cannabidiol Epidyolex® As adjunctive therapy of seizures associated with Dravet Syndrome in conjunction with clobazam, for patients two years of age and older. NCPE Assessment Process complete 8th March 2021
20005 Cannabidiol Epidyolex® As adjunctive therapy of seizures associated with Lennox-Gastaut Syndrome in conjunction with clobazam, for patients two years of age and older. NCPE Assessment Process complete 8th March 2021
21024 Cannabidiol Epidyolex® As adjunctive therapy of seizures associated with tuberous sclerosis complex (TSC) for patients 2 years of age and older. Rapid Review complete 8th July 2021
22013 Caplacizumab Cablivi® Treatment of adults and adolescents aged 12 years and older weighing at least 40 kg experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression. Rapid Review complete 31st March 2022
22049 Capmatinib Tabrecta® Advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy. Rapid Review complete 28th February 2024
- Capsaicin Qutenza® Peripheral neuropathic pain in non-diabetic adults either alone or in combination with other medicinal products for pain. Rapid Review complete 2nd July 2012
20054 Carfilzomib (in combination with daratumumab and dexamethasone) Kyprolis® In combination with daratumumab and dexamethasone (CAR+DAR+DEX) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Awaiting response from Applicant 5th March 2024
- Carfilzomib (in combination with dexamethasone) Kyprolis® For the treatment of adult patients with multiple myeloma who have received at least one prior therapy Rapid Review complete 19th March 2019
- Carfilzomib  (in combination with lenalidomide and dexamethasone)  Kyprolis® For the treatment of adult patients with multiple myeloma who have received at least one prior therapy. NCPE Assessment process complete 19th October 2016
22035 Carglumic acid Ucedane® Treatment of hyperammonaemia due to N-acetyl-glutamate synthase (NAGS) primary deficiency. Rapid Review complete 21st June 2022
- Cariprazine Reagila® For the treatment of schizophrenia in adult patients. Rapid Review complete 19th December 2018
21067 Casirivimab/imdevimab Ronapreve® For the treatment and prevention of COVID-19. Rapid Review complete 1st February 2022
- Catumazomab Removab® For the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible. Rapid Review complete 6th September 2011
22003 Cefiderocol Fetcroja® For the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options. Consideration should be given to official guidance on the appropriate use of antibacterial agents. Rapid Review complete 16th February 2022
- Ceftaroline Zinforo® For the treatment of adult patients with complicated Skin and Soft Tissue Infections (cSSTI) or Community Acquired Pneumonia (CAP). Rapid Review complete 12th October 2012
- Ceftazidime/avibactam Zavicefta® For the treatment of CIAI, cUTI, HAP (including VAP) and gram negative infections due to aerobic Gram-negative organisms in adult patients with limited treatment options. Rapid Review complete 13th June 2017
21003 Ceftazidime/avibactam Zavicefta® For paediatric patients aged three months and older for the treatment of: Complicated intra-abdominal infection (cIAI); Complicated urinary tract infection (cUTI), including pyelonephritis; Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP); Infections due to aerobic Gram-negative organisms in patients with limited treatment options Rapid Review complete 4th March 2021
- Ceftolozane/tazobactam Zerbaxa® For the treatment of complicated urinary tract infections (cUTI), acute pyelonephritis and complicated intra-abdominal infections (cIAI) in adults. Rapid Review complete 26th April 2016
21007 Cemiplimab Libtayo® Is indicated as monotherapy for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for curative surgery or curative radiation. NCPE Assessment Process Complete 24th October 2023
21025 Cenobamate Ontozry® Adjunctive treatment of focal onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least two anti-epileptic medicinal products. NCPE Assessment Process Complete 6th July 2023